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Abstract
Introduction: Post-kala-azar dermal leishmaniasis (PKDL) is a cutaneous complication appearing after treatment of visceral
leishmaniasis, and PKDL patients are considered infectious to sand flies and may therefore play a role in the transmission of
VL. We estimated the risk and risk factors of PKDL in patients with past VL treatment in south-eastern Nepal.
Methods: Between February and May 2010 we traced all patients who had received VL treatment during 2000–2009 in five
high-endemic districts and screened them for PKDL-like skin lesions. Suspected cases were referred to a tertiary care
hospital for confirmation by parasitology (slit skin smear (SSS)) and/or histopathology. We calculated the risk of PKDL using
Kaplan-Meier survival curves and exact logistic regression for risk factors.
Results: Out of 680 past-treated VL patients, 37(5.4%) presented active skin lesions suspect of PKDL during the survey.
Thirty-three of them underwent dermatological assessment, and 16 (2.4%) were ascertained as probable (2) or confirmed
(14) PKDL. Survival analysis showed a 1.4% risk of PKDL within 2 years of VL treatment. All 16 had been previously treated
with sodium stibogluconate (SSG) for their VL. In 5, treatment had not been completed (#21 injections). Skin lesions
developed after a median time interval of 23 months [interquartile range (IQR) 16–40]. We found a higher PKDL rate (29.4%)
in those inadequately treated compared to those who received a full SSG course (2.0%). In the logistic regression model,
unsupervised treatment [odds ratio (OR)=8.58, 95% CI 1.21–374.77], and inadequate SSG treatment for VL in the past
(OR=11.68, 95% CI 2.71–45.47) were significantly associated with PKDL.
Conclusion: The occurrence of PKDL after VL treatment in Nepal is low compared to neighboring countries. Supervised and
adequate treatment of VL seems essential to reduce the risk of PKDL development and active surveillance for PKDL is
needed.
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Introduction
Post-kala-azar dermal leishmaniasis (PKDL) is a late complica-
tion of visceral leishmaniasis (VL), which usually appears several
months after treatment of a VL episode. PKDL is seen in areas
where L.donovani is endemic i.e. in Asia (India, Nepal and
Bangladesh) and in east Africa (Ethiopia, Kenya and Sudan [1].
In the Indian subcontinent, L.donovani is transmitted by the bite of
a female sand fly of the Phlebotomus argentipes species, and the
transmission cycle is considered to be anthroponotic with humans
as the only known infection reservoir [2]. In Nepal, the standard
treatment for VL with SSG was 20 mg/kg/day for 30 days
without any upper limit recommended by WHO and drug was
provided by the program to all government hospital in the
endemic area. Due to associated toxicity and emerging drug
resistance, SSG has been replaced in 2007 by Miltefosine 50 mg
BID.
PKDL is characterized by a spectrum of skin lesions ranging
from hypo-pigmented macules, papules to nodules or combina-
tions over the trunk and face that can be easily confused with other
skin conditions such as vitiligo or leprosy [1,3,4]. So far, no
convincing clinical predictors for PKDL have been identified [1]
and its origin is believed to be multi-factorial and complex [5]. In
Sudan, PKDL is more commonly reported in inadequately or
irregularly treated VL cases [6]. PKDL is also sporadically
reported in individuals without past history of VL [1,7].
The incidence of PKDL varies from country to country for
reasons that are not entirely clear. In Sudan, PKDL was described
in 50–60% of cured VL patients within weeks to a few months
after treatment [1]. In Bangladesh, a cross-sectional survey carried
out in 2009 of patients who suffered from VL in 2002–2007 found
10% of them with active or past PKDL usually occurring within
36 months after VL treatment [8,9]. In India, PKDL is reported in
5–10% of patients treated for VL usually after an interval of 2 to 4
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history of VL [3]. In Nepal VL is endemic in the south eastern
Terai plains bordering the highly endemic districts of Bihar state of
India, but systematic epidemiological data on PKDL are still
lacking.
PKDL patients have probably epidemiological importance in
VL transmission as the lesions can harbour a large amount of
Leishmania parasites, and as such could constitute a reservoir in the
community capable of triggering a new epidemic [9]. As PKDL
causes little or no clinical discomfort, and PKDL treatment with
intramuscular SSG injections is long (3–4 months), painful and
cumbersome, few patients seek treatment [1,5,10–13].
Since 2005, the government of Nepal is involved in a
collaborative effort with India and Bangladesh to reduce VL
incidence to less than 1 per 10 000 population by 2015 [14].
PKDL is not addressed so far in this elimination initiative, which
poses a threat to its success [15]. Better information on the
epidemiology and burden of PKDL might help the national policy
makers and health authorities to develop regional or national
guidelines for its surveillance, control and treatment.
We therefore conducted a retrospective cohort study and
studied the probability and risk factors for PKDL development in
past treated VL cases in five districts of south-eastern Nepal.
Materials and Methods
Study area and population
The study was conducted from February to May 2010, in the
districts of Jhapa, Morang, Sunsari, Saptari, and Siraha, known to
be highly endemic for VL, with incidence rates of 2.0–4.0 per
10,000 person-years (pyr) in 2006/2007. All VL cases that were
notified by these 5 districts during the period 2000–2009 were
taken as the study population. Information to trace the past treated
VL cases (pVL) at household level was obtained through the
district public health office (DPHO) of the districts and the VL
patient database (2000–2009) of B.P. Koirala Institute of Health
Sciences (BPKIHS). BPKIHS is a university hospital located in
Sunsari district that serves as the referral hospital for the region.
The VL treatment centre maintains a patient register with clinical
and epidemiological information. All pVL patients were ap-
proached at their residence by our field workers along with the
vector control officer working at the DPHO. Written informed
consent was obtained from pVL patients before including them
into the study.
Study design and sample size
The study was set up as a retrospective cohort study. Power
calculations were as follows. We defined a priori 2 groups of
patients according to their VL treatment experience: (i) VL
patients treated in the government/private health facilities where
most of the cases were treated on an ambulatory basis
(unsupervised) by local medical assistants, and (ii) VL patients
treated at BPKIHS where VL cases mostly were hospitalized for
the full duration of treatment (supervised). To detect a risk ratio of
5, a sample of 332 was required in each group (treatment in
government/private health facilities vs at BPKIHS) with the two-
sided confidence level of 5%, a power of 80%, and a 1% expected
frequency of PKDL in unexposed (i.e. supervised treatment).
Data collection
Screening for PKDL. Before the initiation of the survey, all
interviewers were trained on the origin of PKDL, the clinical
picture of PKDL lesions, the data collecting tools and methods to
screen for suspected PKDL cases.
Trained field workers identified the pVLs at their residence,
asked for informed consent and interviewed them using a
structured questionnaire. Detailed information on demographic
characteristics and past VL treatment (i.e. date of onset of VL,
health seeking behaviour, place of treatment, date of treatment,
drug of choice, dosage and duration, clinical setting, hospitaliza-
tion during treatment and adherence) was obtained. All pVL cases
were asked about the current or past presence of hypo-pigmented
skin lesions. This question was supported by a pictorial album
showing colour pictures of real PKDL skin lesions. No blood or
other samples were taken. All individuals with PKDL-like skin
lesions found during the survey, they were asked about the time of
onset of hypo- pigmented lesions, mode of onset and treatment
seeking behaviour. The head of household and the pVL case were
also asked whether other individuals within the family had suffered
from VL in the past, and if any of them currently had skin rash. If
during the survey, persons other than those listed in the ‘‘past VL
cases list’’ presented spontaneously with suspected PKDL lesions,
the field workers were asked to refer these cases for further
diagnostic workup as well.
Individuals with current (or past) PKDL-like skin lesions were
counselled and referred to BPKIHS for a complete diagnostic
workup and management. A personalized visiting card with the
name of the health staff member to contact upon their arrival was
given so that their admission at the hospital would be facilitated.
The list of suspected PKDL cases was used to check for
completeness of attendance, and those who did not attend
BPKIHS within 2 months were revisited in their homes a second
time to facilitate the case confirmation.
PKDL cases were treated as per national guideline for kala-azar
elimination. Treatment and treatment outcomes of PKDL will be
documented in a separate study. Costs related to the patient
management (travel, diagnostic workout, medicines, hospitaliza-
tion and minimal care taker allowance for food) were provided,
regardless of the outcome of the diagnosis.
Confirmation procedure
A dermatologist examined all hypo-pigmented skin lesions cases
referred to BPKIHS clinically and took samples for slit skin
Author Summary
Post-kala-azar dermal leishmaniasis (PKDL) is a skin
disorder seen in patients treated for Leishmania donovani
visceral leishmaniasis (VL), a neglected tropical disease that
is fatal if left untreated. In the Indian subcontinent, PKDL is
seen in 5–10% of all past VL cases and is also reported in
some without history of VL. As persons with PKDL do not
feel sick, the disease has only cosmetic significance for the
individual and treatment is rarely sought. However, PKDL
lesions harbour parasites and therefore could represent a
source of transmission, through the bite of female sand
flies. Our study shows that the occurrence of PKDL in
patients with past treated VL is low in Nepal compared to
neighboring countries. Treatment of the original VL
episode with SSG (sodium stibogluconate), inadequate
treatment and treatment on ambulatory basis were
significantly associated with PKDL. Though SSG has since
been replaced by other drugs, counseling and supervision
of adherence to the prescribed VL treatment is of vital
importance to reduce risk of treatment failure and relapse
as well as later development of PKDL. Policy makers should
include surveillance and case management of PKDL in the
VL elimination program.
Risk and Risk Factors for PKDL in Treated VL
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donovani. Differential diagnosis including leprosy, skin tuberculosis
and other fungal infections was done in parallel. Every suspect was
also tested by the rK39 immunochromatographic test for VL (see
below). Based on this assessment, a probable PKDL case was
defined as a person having a past history of VL and multiple hypo-
pigmented skin lesions (macules, papules, plaques or nodules) with
a positive rK39 test but negative for L. donovani in SSE or
histopathological examination. A confirmed PKDL was defined
as a patient with multiple hypo pigmented macules, papules,
plaques or nodules, who was parasite positive in SSE or biopsy.
Laboratory methods
Slit skin smear for L.donovani and Mycobacterium
leprae. Slit skin smear test is routinely done in the department
of dermatology for parasitological examination of PKDL and
leprosy, as follows. The affected area of the skin was cleaned and
dried. The edge of the lesion was squeezed firmly between the
finger and the thumb to drain the blood from the area. Using a
sterile scalpel blade no. 21, a 3–4 mm incision of 3 mm depth was
made into the dermis. The slit skin smear was done by a trained
medical officer under the close supervision of a dermatologist. One
slide was stained with Giemsa and examined for Leishmania donovani
(LD) bodies. The other was stained with Ziehl-Neelsen (Z-N) using
5% sulphuric acid, H2SO4) for Mycobacterium leprae and examined
under oil immersion lens using 1006 oil immersion objectives.
Both slides were examined by two separate experts for
confirmation.
Skin punch biopsy. Punch biopsy is routinely performed in
the Department of Dermatology of BPKIHS for histopathological
examination of PKDL. The skin lesions to be biopsied were
selected, cleaned, dried and anesthetized to limit the discomfort.
Biopsy was performed using a sterile circular blade no. 21 or
trephine attached to a pencil-like handle. The instrument was
rotated down through the epidermis and dermis and punch biopsy
yields a cylindrical core of tissue. The biopsies were gently handled
(usually with a needle) to prevent crush. The wound was closed, if
necessary, with one or two interrupted nylon sutures. The
diagnosis of PKDL was confirmed by standard histological
examination (Giemsa stain) and quantification of Leishmania spp.
rK39. A trained medical officer performed the rK39
immunochromatographic test (Kala-azar Detect
TM Rapid Test,
InBios International, Seattle, WA, USA) as per the manufacturer’s
instructions.
Statistical analysis. Data were cross-checked for data entry
errors by performing cross-tabulation and verifying against the
source document.
We calculated the risk of PKDL (probable+confirmed) among
past treated VL cases over time using life table-methods and
Kaplan-Meier survival curves. The log-rank test was used for
comparison of survival data of different groups to correct for
unequal follow-up times. We assessed risk factors for PKDL
development using single and multiple exact logistic regression
models. Exact logistic regression was used as it allows testing and
estimation of risk factors with sparse data. A backward elimination
strategy was used to identify factors independently associated with
disease; probability for removal was set at 5%. Data were analysed
using EPI info software package version 3.5.1 (Centre for Disease
Control and Prevention, Atlanta, Georgia US) and Stata 10.1
(StataCorp LP, College Sation, Texas US).
Ethical considerations
The Institutional Ethical Review Board of the BPKIHS
Dharan, Nepal, and the corresponding bodies at the University
Antwerp (UZA), Antwerp, Belgium reviewed and approved the
study protocol. Informed consent forms were developed in the
national language and informed consent was obtained from
individuals and from parents for children and adolescents. Written
approval also was obtained from the authority of District Public
Health Offices (DPHO) when information about past VL was
collected from respective districts.
Results
Characteristics of study population
From the records, a total of 742 past VL patients (pVLs) were
identified clustered in 17 highly endemic villages. Field workers
succeeded in tracing 680 (91.6%). All subjects consented to the
study and were interviewed and screened for PKDL-like skin
lesions at their residence [Table 1]. 560 (82.4%) had been treated
with SSG (20 mg/kg/d for 30 consecutive days), 66 (9.7%) with
Amphotericin B, and 54 (7.9%) with Miltefosine. In the SSG
group, 17 (3%) had not completed the treatment (,21 injections).
Half of the VL cases (347 or 51.0%) had been treated at BPKIHS
hospital under supervision during the period of treatment and all
had received complete treatment; 333 (49.0%) were treated at
government/private hospitals on ambulatory basis, including 17
who had been treated in India. In our study, 370 (54.4%) were
male, and the median age of the study population was 28; inter
quartile range (IQR, 15–40) year and the large majority (75.4%)
was aged $15 years.
Screening of PKDL in past VL patients
Among the 680 pVL cases screened 37 (5.4%) individuals
showed hypo pigmented skin lesions. . No pVL patient in the study
reported any skin disorder that since had disappeared spontane-
ously. All the 37 individuals with current skin lesions were referred
to BPKIHS, as well as 2 others with suspect skin lesions who
presented themselves spontaneously to the surveyors: one without
history of clinical VL and a second with VL prior to 2000.
Thirty-three of the 37 referred pVLs reached the BPKIHS
hospital and 16 (2.4% of 680) were diagnosed as PKDL (probable:
2 and confirmed: 14) [Figure 1]. The other 17 were diagnosed as
Pityriasis versicolor (12), other fungal infection (2), and vitiligo (3).
PKDL was also confirmed in the person without VL history, but
not in the person who spontaneously reported with VL before
2000. All 37 suspects tested positive in the rK39 rapid diagnostic
test. HIV status was not tested.
Characteristics of pVL patients with probable and
confirmed PKDL
The median age of the 16 PKDL patients was 23.5 years (IQR,
16–40), and majority (14/16) was aged $15 years. All PKDL cases
had previously been treated for VL with SSG and no PKDL was
found in the treatment with Amphotericin B and Miltefosine. Five
had not completed treatment (less than 21 injections instead of the
Table 1. Risk of PKDL development in past treated VL
patients, life table analysis over time.
Time intervals No. of PKDL Cumulative PKDL rate 95% CI
0–,2 years 9 0.014 0.007–0.027
2–,4 years 5 0.025 0.015–0.042
4–,8 years 2 0.036 0.021–0.062
doi:10.1371/journal.pntd.0001433.t001
Risk and Risk Factors for PKDL in Treated VL
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government/private hospitals on ambulatory basis. The overall
prevalence of PKDL in SSG treatment was 2.9%, 0.3% in
supervised and 4.5% in unsupervised treatment. The median
duration between treatment and onset of skin lesions was 23
months (IQR, 15–41 months). The majority of patients (9/16)
reported that the skin lesions occurred within 24 months after VL
treatment.
Hypo-pigmented macules/plaques were the most common
hypo pigmented lesions and were present first on the face (11/
16), and upper and lower limbs were also affected. In most (13/16)
cases reported, skin lesions appeared gradually from face to lower
extremities and was associated with itching on erythema when
exposed in sun light. Only 4 patients with skin lesions had sought
medical treatment mainly for cosmetic purposes. We didn’t find
any PKDL cases with hepato-and/or splenomegaly and other
associated complications such as post-kala-azar conjunctivitis or
uveitis.
Risk and prevalence of PKDL
Overall, the risk to develop PKDL was 1.4% within two years
after VL treatment, 2.5% within 4 years and 3.6% within 8 years
( s e eT a b l e1 ) .T h er i s ko fP K D Lb yt r e a t m e n t( a d e q u a t eS S G ,
inadequate SSG and other treatments is shown in Figure 2. In the
SSG treated group alone (560 patients) the prevalence rate of
P K D Lw a s2 . 9 % .I nt h eu n i v a r i a t ea n a l y s i s ,P K D Lw a s
significantly associated with unsupervised treatment at govern-
ment/private hospitals (OR=16.28; 95% CI 2.48–689.00) with
inadequate SSG treatment in the past (OR=19.77; 95% CI
4.66–75.00). Both findings remained independently significant in
the multiple logistic regression model. In the univariate analysis,
the risk of PKDL appeared higher in private hospitals
(OR=13.4; 95% CI 0.7–802.7), but this finding was not
significant and was not supported when corrected for treatment.
None of the other assessed risk factors (age, sex, hospitalization
during treatment with SSG) were significantly associated with
PKDL (Table 2).
Discussion
There have been few reports and studies on PKDL from Nepal
[7,16–18], and the frequency and risk factors of PKDL have not
been studied previously. When re-examining a group of patients
who were treated for VL in the previous ten years, we have found
2.4% having PKDL, and 2.9% in the sub-group of those treated
with SSG in particular. The risk estimate for PKDL after VL was
1.4% within 2 years, and 3.6% within 8 years based on Kaplan–
Meier analysis. This risk is lower than that reported in other VL-
endemic areas in the Indian subcontinent [3,8–9,17]. Still, risk
estimates reported are hard to compare due to the unequal follow
up times. The median time from VL treatment to PKDL onset
was 23 months (IQR, 15–41 months). PKDL was more common
in those with incomplete VL treatment and in settings with little
treatment supervision.
A limitation of our study is that enrolment in the cohort was
based on data obtained from one tertiary hospital and govern-
mental health facilities. It is generally assumed that VL is
underreported [19], as patients may be seeking treatment in the
private sector. However, in our region in Nepal only few VL
patients attend private clinics for VL treatment as anti-VL drugs
are provided free-of-charge in the public health structures and are
not available in private pharmacies. No cases of former VL
treatment through private practitioners or pharmacies have ever
been reported to the staff in the VL treatment centre at BPKIHS
(personal communication). This could possibly help explaining
why the frequency of PKDL in Nepal is lower than in the other
reports from the Indian subcontinent.
Figure 1. Recruitment and outcome of PKDL screening survey. Flow chart of study population: from number of patients screened to number
of PKDL cases identified.
doi:10.1371/journal.pntd.0001433.g001
Risk and Risk Factors for PKDL in Treated VL
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of patients diagnosed with VL between 2000 up to 2009; time of
follow-up is variable, which makes the analysis more complex. The
national VL control program initiated miltefosine-based treatment
protocols in 2007, and the 54 pVL cases treated with miltefosine
have been regrouped for the purpose of this analysis with those
who received Amphotericin. Though none of the VL patients in
this group (i.e. Miltefosine or Amphotericin B) developed PKDL,
follow-up time for miltefosine was definitely shorter than for the
other drugs and therefore no final conclusions should be drawn yet
about this drug [8]. Cases of PKDL in patients treated with
Miltefosine have already been reported from India [20].
In another PKDL study conducted in the Fulbaria sub-district
of Mymensingh district in Bangladesh, a cross-sectional survey was
used to detect all past or active VL cases and active PKDL cases in
a time period (2002–2007) and calculated incidences [8]. In this
study clinical signs of PKDL were found in 9.8% of the 813
identified pVLs, almost 2 times higher than the proportion of
suspects found in our study (5.4%) while the time period studied
was shorter. The authors mention however that parasitological
confirmation of PKDL was only done in 10 suspected PKDL cases
and confirmation was only obtained in 4 of these, a confirmation
rate that was similar to ours. In another study in Trishal subdistrict
of Mymensingh in Bangladesh without restriction in time of onset
of VL [9] 52 PKDL suspects were identified for 235 pVLs, of
which 18 (7.6%) were as probable cases and 9 (3.8%) were
ultimately confirmed. Neither of both studies estimated the risk for
PKDL over time using survival analysis.
The single cross-sectional dermatological assessment may have
made us underestimate the true incidence of PKDL, though no
self-healing has been described for this pathology. No pVL patient
in the study reported any symptoms of PKDL that since had
disappeared - spontaneously or after treatment. One case of
PKDL without antecedents of VL treatment was identified during
the survey and confirmed at BPKIHS. In the cross-sectional
surveys in Bangladesh, PKDL without previous VL accounted for
10% of all PKDL cases [8–9]. In Nepal an earlier study at
BPKIHS reviewing the 22 cases of PKDL that were diagnosed
between 1998 and 2000, only 1 case had no clinical VL history
[7]. It is thus unlikely that a high number of PKDL cases without
previous VL have been missed in our survey.
Median time of onset and clinical features of PKDL patients
were all consistent with the findings from India and Bangladesh
[7,12,21]. All 16 PKDL cases had lesions in the face, but only four
had sought treatment for PKDL. All four were female and 3 were
unmarried.
In our study, the risk analysis only included data on VL history
and treatment, and did not look into clinical markers such as
Figure 2. Risk of PKDL in three VL-treatment groups, Kaplan-Meier survival analysis. Kaplan-Meier survival analysis for three types of VL
treatment.
doi:10.1371/journal.pntd.0001433.g002
Risk and Risk Factors for PKDL in Treated VL
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cytokines [22–23]. HIV prevalence is low in Nepal and even more
so in the rural population affected by VL. Inadequate treatment
received by pVLs in the past represented the most significant risk
factor for PKDL (OR 11.68, 95% CI 2.71–45.47). This is in line
with earlier findings from Sudan where inadequate dosage and
duration, and irregular treatment were important predictors for
PKDL [6,23]. Without supervision of treatment and adherence
counselling, patients may indeed abandon treatment earlier than
prescribed, as clinical improvement usually appears within the first
week of VL treatment, and there is little incentive to continue the
painful intramuscular injections with SSG. In Nepal, VL
treatment is provided for free to overcome financial barriers, but
in some cases, treatment interruption was reportedly due to stock
shortages of SSG at the hospital level. Treatment compliance
should therefore be correctly monitored by clinicians and
programmes, and all patients should be counselled about the
importance of treatment adherence. This is important not only to
avoid development of PKDL but also to reduce risks of treatment
failure and development of drug resistance.
It should be clear that PKDL is a multi-factorial phenomenon of
complex origin [5] whereby drug related factors are not the only
reasons for PKDL development. Host and parasite factors need to
be further elucidated [24].
In conclusion, the occurrence of PKDL after VL treatment is
relatively rare in Nepal compared to the two neighbouring
countries involved in the VL Elimination Initiative. SSG,
ambulatory treatment at government health facilities and
inadequate treatment for VL in the past were significantly
associated with PKDL. Counselling and supervision of treatment
adherence in VL seems therefore essential to reduce PKDL
incidence in the future, even if SSG is no longer used in Nepal.
Reporting of cases of PKDL should be an integral part of the
surveillance and monitoring system. Early identification can be
improved by counselling VL patients on the risks and the signs of
PKDL during their treatment.
Ultimately, the burden of PKDL can only be efficiently tackled
if a more effective, affordable and short treatment can be offered
to the patients.
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Table 2. Risk factors for PKDL development in past treated VL patients, exact logistic regression.
Factors Past VL (no.) PKDL Unadjusted OR
a 95% CI
b Adjusted OR 95% CI
no. (%)
Age (year) median (IQR)
d 680 28 (15;40)
#14 year 167 3 (1.8) referent
15–29 year 194 6 (3.1) 1.74 0.37–10.93
30–44 year 189 4 (2.1) 1.18 0.20–8.18
$45 year 130 3 (2.3) 1.29 0.17–9.80
Gender
Male 370 8 (2.2) referent
Female 310 8 (2.6) 1.20 0.39–3.71
Drug used for VL treatment
Adequate SSG
s treatment 543 11 (2.0) referent referent
Inadequate SSG treatment (#20 injection) 17 5 (29.4) 19.77 4.66–75.00 11.68 2.71–
45.47
Other treatment (Miltefosine & Amphotericin B) 120 0 (0.0) 0.29* 0.00–1.80 0.67* 0.00–
4.59
Supervised treatment with SSG at BPKIHS
Adequate treatment 247 1 (0.4)
Inadequate treatment (#20 injection) 0 0 (0.0)
Unsupervised treatment with SSG at other places (Govt. & pvt)
Adequate treatment 296 10 (3.4)
Inadequate treatment (#20 injection) 17 5 (29.4)
Hospitalization during treatment with SSG
No 334 12 (3.6) referent
Yes 226 4 (1.8) 0.45 0.14–1.40
aOR : odds ratio;
bCI: confidence interval;
dIQR: Inter quartile range;
sSSG : Sodium stibogluconate.
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